Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ejca.2008.06.044
DC FieldValue
dc.titlePotential roles for the PIM1 kinase in human cancer - A molecular and therapeutic appraisal
dc.contributor.authorShah, N.
dc.contributor.authorYeoh, K.-G.
dc.contributor.authorChen, C.S.
dc.contributor.authorSalto-Tellez, M.
dc.contributor.authorThorn, S.
dc.contributor.authorLilly, M.B.
dc.date.accessioned2012-05-29T02:21:40Z
dc.date.available2012-05-29T02:21:40Z
dc.date.issued2008
dc.identifier.citationShah, N., Yeoh, K.-G., Chen, C.S., Salto-Tellez, M., Thorn, S., Lilly, M.B. (2008). Potential roles for the PIM1 kinase in human cancer - A molecular and therapeutic appraisal. European Journal of Cancer 44 (15) : 2144-2151. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ejca.2008.06.044
dc.identifier.issn09598049
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/33180
dc.description.abstractIn vitro experiments have shown the PIM1 kinase to have diverse biological roles in cell survival, proliferation and differentiation. In humans, PIM1 is often expressed in both normal and transformed cells. The PIM1 kinase is a true oncogene implicated in early transformation and tumour progression in haematopoietic malignancies and prostate carcinomas. It is associated with aggressive subgroups of lymphoma, is a marker of poor prognosis in prostate carcinomas and has been suggested to have a role in hormone insensitivity of prostate malignancies. PIM1 has a possible role in other carcinomas with 6p21 genomic alterations. On one hand, PIM1 (due to its role in malignancy) appears to be a promising target for drug development programmes but, on the other hand, the complexity of its molecular structure has posed challenges in the development of PIM1 inhibitors. In this review we discuss PIM1 expression in human tissues (including some new data from our laboratory), its role in human malignancies, as well as the possibilities and challenges in the development of target therapy for PIM1. © 2008 Elsevier Ltd. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.ejca.2008.06.044
dc.sourceScopus
dc.subjectCarcinomas
dc.subjectKinase
dc.subjectLymphomas
dc.subjectPIM1
dc.subjectTarget inhibitors
dc.typeArticle
dc.contributor.departmentNATIONAL UNIVERSITY MEDICAL INSTITUTES
dc.contributor.departmentMEDICINE
dc.contributor.departmentPATHOLOGY
dc.description.doi10.1016/j.ejca.2008.06.044
dc.description.sourcetitleEuropean Journal of Cancer
dc.description.volume44
dc.description.issue15
dc.description.page2144-2151
dc.description.codenEJCAE
dc.identifier.isiut000261020800011
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

112
checked on Apr 12, 2021

WEB OF SCIENCETM
Citations

108
checked on Apr 12, 2021

Page view(s)

193
checked on Apr 14, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.